Muhammad Khan, MD
Cardiovascular Disease · Carbondale, ILNPI 1144412859
Payments from drug & device makers
What this record shows
This record is dominated by grants: $20,000 of the $22,119 with a category attached, or 90.4%. 15 manufacturers reported payments, led by Abbott at 54.0% of the total. Reporting peaked in 2022 at $10,211 and has fallen 93.1% since, to $706 in 2025. Among cardiovascular disease clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 74 payments — averaging $298.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$12K
- Medtronic$5K
- Boston Scientific$4K
- Biosense Webster, Inc.$591
- Abiomed$171
- E.r. Squibb & Sons, L.L.C.$104
- plus $199 from 9 others
What the payments were for
- Grants$20,00090%
- Travel & lodging$2471%
- Food & beverage$1,8718%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 30 | $11,939 |
| Medtronic | 7 | $5,208 |
| Boston Scientific | 3 | $3,906 |
| Biosense Webster, Inc. | 21 | $591 |
| Abiomed | 2 | $171 |
| E.r. Squibb & Sons, L.L.C. | 1 | $104 |
| Boehringer Ingelheim | 2 | $42 |
| Philips North America LLC | 1 | $32 |
| Novartis | 1 | $28 |
| Stryker | 1 | $21 |
| AstraZeneca | 1 | $18 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $17 |
| Novo Nordisk | 1 | $15 |
| Lantheus Medical Imaging, Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,119 in reported general payments places this provider in the 90th percentile of 932 cardiovascular disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 13 | $12,378 |
| Potassium Chloride | 13 | $844 |
| Metoprolol Succinate | 34 | $645 |
| Flecainide Acetate | 14 | $582 |
| Amiodarone Hcl | 24 | $131 |
| Furosemide | 11 | $49 |
| Lisinopril | 14 | $30 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Carbondale
- Sandeep NathanChicago$892K
- Alan BrownNaperville$858K
- Azmey MatariehElgin$762K
- Jay AlexanderBannockburn$744K
- Niraj VarmaMaywood$522K
- Boaz AvitallChicago$366K
- Akhil NarangChicago$363K
- Mark RabbatMaywood$363K
- Michael DavidsonChicago$317K
- Robert KochLibertyville$298K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.